Linerixibat targets pruritus pathobiology in PBC by blocking ileal bile acid reuptake, aiming to lower circulating pruritogenic bile acid–related mediators. GLISTEN demonstrated greater 24-week WI-NRS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results